{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T14:08:04Z","timestamp":1790431684336,"version":"4.1.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2019,9,10]],"date-time":"2019-09-10T00:00:00Z","timestamp":1568073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,9,10]],"date-time":"2019-09-10T00:00:00Z","timestamp":1568073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004063","name":"Knut och Alice Wallenbergs Stiftelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004063","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007232","name":"Radiumhemmets Forskningsfonder","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007232","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Current treatment modalities for disseminated cutaneous malignant melanoma (CMM) improve survival; however, relapses are common. A number of receptor tyrosine kinases (RTKs) including EGFR and MET have been reported to be involved in CMM metastasis and in the development of resistance to therapy, targeting the mitogen-activated protein kinase (MAPK pathway). IHC analysis showed that patients with higher MET protein expression had a significantly shorter overall survival. In addition, silencing of MET caused an upregulation of EGFR and p-AKT, which was abrogated by concomitant silencing of MET and EGFR in CMM cells resistant to MAPK-targeting drugs. We therefore explored novel treatment strategies using clinically approved drugs afatinib (ERBB family inhibitor) and crizotinib (MET inhibitor), to simultaneously block MET and ERBB family RTKs. The effects of the combination were assessed in cell culture and spheroid models using established CMM and patient-derived short-term cell lines, and an in vivo xenograft mouse model. The combination had a synergistic effect, promoting cell death, concomitant with a potent downregulation of migratory and invasive capacity independent of their <jats:italic>BRAF\/NRAS<\/jats:italic> mutational status. Furthermore, the combination attenuated tumor growth rate, as ascertained by the significant reduction of Ki67 expression and induced DNA damage in vivo. Importantly, this combination therapy had minimal therapy-related toxicity in mice. Lastly, the cell cycle G2 checkpoint kinase WEE1 and the RTK IGF1R, non-canonical targets, were altered upon exposure to the combination. Knockdown of WEE1 abrogated the combination-mediated effects on cell migration and proliferation in <jats:italic>BRAF<\/jats:italic> mutant BRAF inhibitor-sensitive cells, whereas WEE1 silencing alone inhibited cell migration in <jats:italic>NRAS<\/jats:italic> mutant cells. In summary, our results show that afatinib and crizotinib in combination is a promising alternative targeted therapy option for CMM patients, irrespective of <jats:italic>BRAF\/NRAS<\/jats:italic> mutational status, as well as for cases where resistance has developed towards <jats:italic>BRAF<\/jats:italic> inhibitors.<\/jats:p>","DOI":"10.1038\/s41419-019-1875-8","type":"journal-article","created":{"date-parts":[[2019,9,10]],"date-time":"2019-09-10T15:02:38Z","timestamp":1568127758000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Combining ERBB family and MET inhibitors is an effective therapeutic strategy in cutaneous malignant melanoma independent of BRAF\/NRAS mutation status"],"prefix":"10.1038","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2019-8072","authenticated-orcid":false,"given":"Ishani","family":"Das","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margareta","family":"Wilhelm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"H\u00f6iom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6853-8726","authenticated-orcid":false,"given":"Rodolfo","family":"Franco Marquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda","family":"Costa Svedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Hansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Tuominen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0524-2346","authenticated-orcid":false,"given":"Suzanne","family":"Egyh\u00e0zi Brage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,10]]},"reference":[{"key":"1875_CR1","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/nrc.2017.43","volume":"17","author":"R Ossio","year":"2017","unstructured":"Ossio, R., Roldan-Marin, R., Martinez-Said, H., Adams, D. J. & Robles-Espinoza, C. D. Melanoma: a global perspective. Nat. Rev. Cancer 17, 393\u2013394 (2017).","journal-title":"Nat. Rev. Cancer"},{"key":"1875_CR2","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/nature00766","volume":"417","author":"H Davies","year":"2002","unstructured":"Davies, H. et al. Mutations of the BRAF gene in human cancer. Nature 417, 949\u2013954, https:\/\/doi.org\/10.1038\/nature00766 (2002).","journal-title":"Nature"},{"issue":"7","key":"1875_CR3","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1200\/JCO.2017.74.1025","volume":"36","author":"Georgina V. Long","year":"2018","unstructured":"Long, G. V. et al. Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib. J. Clin. Oncol. 36, 667\u2013673, https:\/\/doi.org\/10.1200\/JCO.2017.74.1025 (2018).","journal-title":"Journal of Clinical Oncology"},{"key":"1875_CR4","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/nature13121","volume":"508","author":"C Sun","year":"2014","unstructured":"Sun, C. et al. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature 508, 118\u2013122, https:\/\/doi.org\/10.1038\/nature13121 (2014).","journal-title":"Nature"},{"key":"1875_CR5","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1158\/2159-8290.CD-12-0386","volume":"3","author":"MR Girotti","year":"2013","unstructured":"Girotti, M. R. et al. Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma. Cancer Discov. 3, 158\u2013167, https:\/\/doi.org\/10.1158\/2159-8290.CD-12-0386 (2013).","journal-title":"Cancer Discov."},{"key":"1875_CR6","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S1470-2045(13)70024-X","volume":"14","author":"PA Ascierto","year":"2013","unstructured":"Ascierto, P. A. et al. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol. 14, 249\u2013256, https:\/\/doi.org\/10.1016\/S1470-2045(13)70024-X (2013).","journal-title":"Lancet Oncol."},{"key":"1875_CR7","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ejca.2018.04.010","volume":"98","author":"Michael Constantin Kirchberger","year":"2018","unstructured":"Kirchberger, M. C. et al. MEK inhibition may increase survival of NRAS-mutated melanoma patients treated with checkpoint blockade: Results of a retrospective multicentre analysis of 364 patients. Eur. J. Cancer 98, 10\u201316, https:\/\/doi.org\/10.1016\/j.ejca.2018.04.010 (2018).","journal-title":"European Journal of Cancer"},{"issue":"2","key":"1875_CR8","doi-asserted-by":"publisher","first-page":"397-404.e9","DOI":"10.1016\/j.cell.2016.08.069","volume":"167","author":"Jianjun Gao","year":"2016","unstructured":"Gao, J. et al. Loss of IFN-gamma pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy. Cell 167, 397\u2013404 e399, https:\/\/doi.org\/10.1016\/j.cell.2016.08.069 (2016).","journal-title":"Cell"},{"key":"1875_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-02674-y","volume":"9","author":"M Werner-Klein","year":"2018","unstructured":"Werner-Klein, M. et al. Genetic alterations driving metastatic colony formation are acquired outside of the primary tumour in melanoma. Nat. Commun. 9, 595, https:\/\/doi.org\/10.1038\/s41467-017-02674-y (2018).","journal-title":"Nat. Commun."},{"key":"1875_CR10","doi-asserted-by":"publisher","first-page":"9","DOI":"10.4103\/1477-3163.44372","volume":"7","author":"N Puri","year":"2008","unstructured":"Puri, N. & Salgia, R. Synergism of EGFR and c-Met pathways, cross-talk and inhibition, in non-small cell lung cancer. J. Carcinog. 7, 9 (2008).","journal-title":"J. Carcinog."},{"key":"1875_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0084700","volume":"8","author":"S Nanjo","year":"2013","unstructured":"Nanjo, S. et al. Ability of the Met kinase inhibitor crizotinib and new generation EGFR inhibitors to overcome resistance to EGFR inhibitors. PLoS ONE 8, e84700, https:\/\/doi.org\/10.1371\/journal.pone.0084700 (2013).","journal-title":"PLoS ONE"},{"issue":"7","key":"1875_CR12","doi-asserted-by":"publisher","first-page":"e110","DOI":"10.1038\/oncsis.2014.23","volume":"3","author":"S Tiwary","year":"2014","unstructured":"Tiwary, S. et al. ERBB3 is required for metastasis formation of melanoma cells. Oncogenesis 3, e110, https:\/\/doi.org\/10.1038\/oncsis.2014.23 (2014).","journal-title":"Oncogenesis"},{"key":"1875_CR13","doi-asserted-by":"publisher","first-page":"4015","DOI":"10.1073\/pnas.1216013110","volume":"110","author":"C Posch","year":"2013","unstructured":"Posch, C. et al. Combined targeting of MEK and PI3K\/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo. Proc. Natl Acad. Sci. USA 110, 4015\u20134020, https:\/\/doi.org\/10.1073\/pnas.1216013110 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1875_CR14","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1038\/nature09626","volume":"468","author":"R Nazarian","year":"2010","unstructured":"Nazarian, R. et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468, 973\u2013977, https:\/\/doi.org\/10.1038\/nature09626 (2010).","journal-title":"Nature"},{"issue":"6","key":"1875_CR15","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.ccr.2010.11.023","volume":"18","author":"Jessie Villanueva","year":"2010","unstructured":"Villanueva, J. et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R\/PI3K. Cancer Cell 18, 683\u2013695, https:\/\/doi.org\/10.1016\/j.ccr.2010.11.023 (2010).","journal-title":"Cancer Cell"},{"key":"1875_CR16","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401\u2013404, https:\/\/doi.org\/10.1158\/2159-8290.CD-12-0095 (2012).","journal-title":"Cancer Discov."},{"key":"1875_CR17","doi-asserted-by":"publisher","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","volume":"6","author":"J Gao","year":"2013","unstructured":"Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 6, pl1, https:\/\/doi.org\/10.1126\/scisignal.2004088 (2013).","journal-title":"Sci. Signal."},{"issue":"8","key":"1875_CR18","doi-asserted-by":"publisher","first-page":"e3029","DOI":"10.1038\/cddis.2017.406","volume":"8","author":"Alireza Azimi","year":"2017","unstructured":"Azimi, A. et al. Silencing FLI or targeting CD13\/ANPEP lead to dephosphorylation of EPHA2, a mediator of BRAF inhibitor resistance, and induce growth arrest or apoptosis in melanoma cells. Cell Death Dis 8, e3029, https:\/\/doi.org\/10.1038\/cddis.2017.406 (2017).","journal-title":"Cell Death & Disease"},{"key":"1875_CR19","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s40265-013-0170-8","volume":"74","author":"GM Keating","year":"2014","unstructured":"Keating, G. M. Afatinib: a review of its use in the treatment of advanced non-small cell lung cancer. Drugs 74, 207\u2013221, https:\/\/doi.org\/10.1007\/s40265-013-0170-8 (2014).","journal-title":"Drugs"},{"key":"1875_CR20","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1097\/CMR.0b013e32832c6339","volume":"19","author":"EA Djerf","year":"2009","unstructured":"Djerf, E. A. et al. ErbB receptor tyrosine kinases contribute to proliferation of malignant melanoma cells: inhibition by gefitinib (ZD1839). Melanoma Res. 19, 156\u2013166, https:\/\/doi.org\/10.1097\/CMR.0b013e32832c6339 (2009).","journal-title":"Melanoma Res."},{"key":"1875_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0795-z","volume":"17","author":"L Demkova","year":"2018","unstructured":"Demkova, L. & Kucerova, L. Role of the HGF\/c-MET tyrosine kinase inhibitors in metastasic melanoma. Mol. Cancer 17, 26, https:\/\/doi.org\/10.1186\/s12943-018-0795-z (2018).","journal-title":"Mol. Cancer"},{"key":"1875_CR22","doi-asserted-by":"publisher","first-page":"40268","DOI":"10.18632\/oncotarget.5592","volume":"6","author":"L You","year":"2015","unstructured":"You, L. et al. Crizotinib induces autophagy through inhibition of the STAT3 pathway in multiple lung cancer cell lines. Oncotarget 6, 40268\u201340282, https:\/\/doi.org\/10.18632\/oncotarget.5592 (2015).","journal-title":"Oncotarget"},{"key":"1875_CR23","doi-asserted-by":"publisher","unstructured":"Hu, X. X. et al. Blocking autophagy improves the anti-tumor activity of afatinib in lung adenocarcinoma with activating EGFR mutations in vitro and in vivo. Sci. Rep. Uk 7, ARTN 4559 https:\/\/doi.org\/10.1038\/s41598-017-04258-8 (2017).","DOI":"10.1038\/s41598-017-04258-8"},{"key":"1875_CR24","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1097\/CMR.0000000000000403","volume":"27","author":"JP Robinson","year":"2017","unstructured":"Robinson, J. P. et al. Resistance mechanisms to genetic suppression of mutant NRAS in melanoma. Melanoma Res. 27, 545\u2013557, https:\/\/doi.org\/10.1097\/CMR.0000000000000403 (2017).","journal-title":"Melanoma Res."},{"key":"1875_CR25","first-page":"5157","volume":"58","author":"T Otsuka","year":"1998","unstructured":"Otsuka, T. et al. c-Met autocrine activation induces development of malignant melanoma and acquisition of the metastatic phenotype. Cancer Res. 58, 5157\u20135167 (1998).","journal-title":"Cancer Res."},{"issue":"5","key":"1875_CR26","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.cellsig.2015.01.020","volume":"27","author":"Julio Vera","year":"2015","unstructured":"Vera, J. et al. Chk1 and Wee1 control genotoxic-stress induced G2-M arrest in melanoma cells. Cell Signal 27, 951\u2013960, https:\/\/doi.org\/10.1016\/j.cellsig.2015.01.020 (2015).","journal-title":"Cellular Signalling"},{"key":"1875_CR27","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.2174\/138920111798808437","volume":"12","author":"A Busse","year":"2011","unstructured":"Busse, A. & Keilholz, U. Role of TGF-beta in melanoma. Curr. Pharm. Biotechnol. 12, 2165\u20132175 (2011).","journal-title":"Curr. Pharm. Biotechnol."},{"key":"1875_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-015-0404-3","volume":"14","author":"KA Cohen-Solal","year":"2015","unstructured":"Cohen-Solal, K. A., Boregowda, R. K. & Lasfar, A. RUNX2 and the PI3K\/AKT axis reciprocal activation as a driving force for tumor progression. Mol. Cancer 14, 137, https:\/\/doi.org\/10.1186\/s12943-015-0404-3 (2015).","journal-title":"Mol. Cancer"},{"key":"1875_CR29","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ccr.2010.10.031","volume":"19","author":"S Chandarlapaty","year":"2011","unstructured":"Chandarlapaty, S. et al. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 19, 58\u201371, https:\/\/doi.org\/10.1016\/j.ccr.2010.10.031 (2011).","journal-title":"Cancer Cell"},{"issue":"10","key":"1875_CR30","doi-asserted-by":"publisher","first-page":"e1488359","DOI":"10.1080\/2162402X.2018.1488359","volume":"7","author":"Lillian Sun","year":"2018","unstructured":"Sun, L. et al. WEE1 kinase inhibition reverses G2\/M cell cycle checkpoint activation to sensitize cancer cells to immunotherapy. Oncoimmunology 7, e1488359, https:\/\/doi.org\/10.1080\/2162402X.2018.1488359 (2018).","journal-title":"OncoImmunology"},{"key":"1875_CR31","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13046-019-1038-x","volume":"38","author":"C Margue","year":"2019","unstructured":"Margue, C. et al. Kinase inhibitor library screening identifies synergistic drug combinations effective in sensitive and resistant melanoma cells. J. Exp. Clin. Cancer Res. 38, 56, https:\/\/doi.org\/10.1186\/s13046-019-1038-x (2019).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"1875_CR32","doi-asserted-by":"publisher","first-page":"688","DOI":"10.3324\/haematol.2013.093187","volume":"99","author":"L Chaudhuri","year":"2014","unstructured":"Chaudhuri, L. et al. CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo. Haematologica 99, 688\u2013696, https:\/\/doi.org\/10.3324\/haematol.2013.093187 (2014).","journal-title":"Haematologica"},{"key":"1875_CR33","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1080\/15384047.2017.1360446","volume":"19","author":"OF Kuzu","year":"2018","unstructured":"Kuzu, O. F. et al. Identification of WEE1 as a target to make AKT inhibition more effective in melanoma. Cancer Biol. Ther. 19, 53\u201362, https:\/\/doi.org\/10.1080\/15384047.2017.1360446 (2018).","journal-title":"Cancer Biol. Ther."},{"key":"1875_CR34","doi-asserted-by":"publisher","first-page":"6574","DOI":"10.1038\/sj.onc.1209674","volume":"25","author":"AH Yeh","year":"2006","unstructured":"Yeh, A. H., Bohula, E. A. & Macaulay, V. M. Human melanoma cells expressing V600E B-RAF are susceptible to IGF1R targeting by small interfering RNAs. Oncogene 25, 6574\u20136581, https:\/\/doi.org\/10.1038\/sj.onc.1209674 (2006).","journal-title":"Oncogene"},{"key":"1875_CR35","doi-asserted-by":"publisher","first-page":"39877","DOI":"10.18632\/oncotarget.5631","volume":"6","author":"R Ramcharan","year":"2015","unstructured":"Ramcharan, R. et al. IGF-1R inhibition induces schedule-dependent sensitization of human melanoma to temozolomide. Oncotarget 6, 39877\u201339890, https:\/\/doi.org\/10.18632\/oncotarget.5631 (2015).","journal-title":"Oncotarget"},{"key":"1875_CR36","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S1470-2045(09)70137-8","volume":"10","author":"MV Karamouzis","year":"2009","unstructured":"Karamouzis, M. V., Konstantinopoulos, P. A., Papavassiliou, A. G. & Targeting, M. E. T. as a strategy to overcome crosstalk-related resistance to EGFR inhibitors. Lancet Oncol. 10, 709\u2013717, https:\/\/doi.org\/10.1016\/S1470-2045(09)70137-8 (2009).","journal-title":"Lancet Oncol."},{"key":"1875_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-015-0319-z","volume":"14","author":"S Gusenbauer","year":"2015","unstructured":"Gusenbauer, S., Zanucco, E., Knyazev, P. & Ullrich, A. Erk2 but not Erk1 regulates crosstalk between Met and EGFR in squamous cell carcinoma cell lines. Mol. Cancer 14, 54, https:\/\/doi.org\/10.1186\/s12943-015-0319-z (2015).","journal-title":"Mol. Cancer"},{"key":"1875_CR38","doi-asserted-by":"publisher","first-page":"8573","DOI":"10.1073\/pnas.1302107110","volume":"110","author":"M Acunzo","year":"2013","unstructured":"Acunzo, M. et al. Cross-talk between MET and EGFR in non-small cell lung cancer involves miR-27a and Sprouty2. Proc. Natl Acad. Sci. USA 110, 8573\u20138578, https:\/\/doi.org\/10.1073\/pnas.1302107110 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1875_CR39","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1158\/2159-8290.CD-12-0558","volume":"3","author":"A Bardelli","year":"2013","unstructured":"Bardelli, A. et al. Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov. 3, 658\u2013673, https:\/\/doi.org\/10.1158\/2159-8290.CD-12-0558 (2013).","journal-title":"Cancer Discov."},{"key":"1875_CR40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0059708","volume":"8","author":"G Chen","year":"2013","unstructured":"Chen, G. et al. Synergistic effect of afatinib with su11274 in non-small cell lung cancer cells resistant to gefitinib or erlotinib. PLoS ONE 8, e59708, https:\/\/doi.org\/10.1371\/journal.pone.0059708 (2013).","journal-title":"PLoS ONE"},{"key":"1875_CR41","doi-asserted-by":"publisher","first-page":"18254","DOI":"10.18632\/oncotarget.24810","volume":"9","author":"E Dratkiewicz","year":"2018","unstructured":"Dratkiewicz, E., Pietraszek-Gremplewicz, K., Simiczyjew, A., Mazur, A. J. & Nowak, D. Gefitinib or lapatinib with foretinib synergistically induce a cytotoxic effect in melanoma cell lines. Oncotarget 9, 18254\u201318268, https:\/\/doi.org\/10.18632\/oncotarget.24810 (2018).","journal-title":"Oncotarget"},{"key":"1875_CR42","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0038254","volume":"7","author":"GI Magnussen","year":"2012","unstructured":"Magnussen, G. I. et al. High expression of Wee1 is associated with poor disease-free survival in malignant melanoma: potential for targeted therapy. PLoS ONE 7, e38254, https:\/\/doi.org\/10.1371\/journal.pone.0038254 (2012).","journal-title":"PLoS ONE"},{"key":"1875_CR43","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/leu.2014.149","volume":"29","author":"E Weisberg","year":"2015","unstructured":"Weisberg, E. et al. Identification of Wee1 as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies. Leukemia 29, 27\u201337, https:\/\/doi.org\/10.1038\/leu.2014.149 (2015).","journal-title":"Leukemia"},{"key":"1875_CR44","first-page":"203","volume":"7","author":"L Huang","year":"2017","unstructured":"Huang, L. et al. Combinational therapy of crizotinib and afatinib for malignant pleural mesothelioma. Am. J. Cancer Res. 7, 203\u2013217 (2017).","journal-title":"Am. J. Cancer Res."},{"key":"1875_CR45","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1111\/cas.13571","volume":"109","author":"H Torigoe","year":"2018","unstructured":"Torigoe, H. et al. Therapeutic strategies for afatinib-resistant lung cancer harboring HER2 alterations. Cancer Sci. 109, 1493\u20131502, https:\/\/doi.org\/10.1111\/cas.13571 (2018).","journal-title":"Cancer Sci."}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-019-1875-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-019-1875-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-019-1875-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T17:31:53Z","timestamp":1671211913000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-019-1875-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,10]]},"references-count":45,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2019,9]]}},"alternative-id":["1875"],"URL":"https:\/\/doi.org\/10.1038\/s41419-019-1875-8","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,10]]},"assertion":[{"value":"22 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"663"}}